tradingkey.logo
tradingkey.logo
Search

Biontech SE

BNTX
Add to Watchlist
93.750USD
+0.410+0.44%
Market hours ETQuotes delayed by 15 min
23.71BMarket Cap
LossP/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D

Today

+0.44%

5 Days

-5.64%

1 Month

-1.83%

6 Months

-13.71%

Year to Date

-1.52%

1 Year

+1.06%

TradingKey Stock Score of Biontech SE

Currency: USD Updated: 2026-05-11

Key Insights

Biontech SE's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 37 out of 383 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 129.61.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Biontech SE's Score

Industry at a Glance

Industry Ranking
37 / 383
Overall Ranking
136 / 4492
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Biontech SE Highlights

StrengthsRisks
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Fairly Valued
The company’s latest PE is -21.27, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 51.86M shares, decreasing 2.43% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 74.54K shares of this stock.

Analyst Rating

Based on 20 analysts
Buy
Current Rating
129.606
Target Price
+37.70%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Biontech SE News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Biontech SE Info

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Ticker SymbolBNTX
CompanyBiontech SE
CEOSahin (Ugur)
Websitehttps://www.biontech.com/
KeyAI